PRECLINICAL CRO SERVICES FOR DRUGS TARGETING METABOLIC DISORDERS
Physiogenex provides preclinical in vivo and ex vivo CRO services with more than 15 years of expertise in evaluating drugs targeting metabolic disorders such as obesity, diabetes, NASH, fibrosis, diabetic nephropathy, cardiovascular complications, dyslipidemia and atherosclerosis.
We develop in-house and gold standard preclinical models in our cutting-edge facilities near Toulouse, France.
Along with our preclinical CRO services, we offer consulting services adapted to the specific needs of our clients. Our metabolic diseases experts offer their many years of experience in drug development to help you design and run efficient and cost-effective studies to shorten your product’s time to market.
STATE OF THE ART CRO FACILITIES
Physiogenex is located near Toulouse (France) in brand new facilities . Our technical platform is equipped with all appropriate devices to ensure high quality CRO services and reliable study results to our clients.
High success rate customer satisfaction in 2021: 97.5%
When is your turn?
THEY TRUST US
We work with more than 100 biopharmaceutical, nutraceutical and agrifood companies
LATEST NEWS ABOUT PHYSIOGENEX
Physiogenex to present its obese/type 2 diabetic rat models of nephropathy at 59th ERA congress in Paris, France
Physiogenex will be presenting its two obese/type 2 diabetic rat models of nephropathy at the 59th ERA congress in Paris France May 19-22th, 2022. The first...
Physiogenex to present its obese hamster model of severe COVID-19 at Vascular Discovery 2022 in Seattle, WA, USA
Physiogenex will be presenting the effects of SARS-CoV-2 infection on dyslipidemia and NASH in its obese hamster model at Vascular Discovery 2022, to be held...
Physiogenex to present its obese NASH hamster model at the International Conference on Fatty Liver 2022 (April 28-30)
Physiogenex will be presenting the cardiometabolic benefits of the GLP-1 receptor agonist semaglutide in its innovative obese NASH hamster model on April...